{"id":11549,"date":"2012-10-09T10:35:57","date_gmt":"2012-10-09T14:35:57","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=11549"},"modified":"2012-10-09T10:35:57","modified_gmt":"2012-10-09T14:35:57","slug":"immunotherapy-developer-gains-4-9m-in-series-b-funds","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=11549","title":{"rendered":"Immunotherapy Developer Gains $4.9M in Series B Funds"},"content":{"rendered":"<p><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/CashMoney_200.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-full wp-image-291\" title=\"CashMoney_200\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/CashMoney_200.jpg\" alt=\"Loose bills of multiple denominations (borman818)\" width=\"200\" height=\"200\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/CashMoney_200.jpg 200w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/CashMoney_200-150x150.jpg 150w\" sizes=\"auto, (max-width: 200px) 100vw, 200px\" \/><\/a><a href=\"http:\/\/www.gliknik.com\/news\/press-release-100812.pdf\">Gliknik Inc.<\/a>, a biopharmaceutical company in Baltimore, raised $4.9 million in series B funds, the second series of financing after initial start-up. Baxter Ventures led the funding round, joined by the company&#8217;s existing investors.<\/p>\n<p>Gliknik is a developer of therapies for patients with cancer and immune disorders that use the power of the immune system to fight disease. Its technology platform, called <a href=\"http:\/\/www.gliknik.com\/research\/stradomer.php\">Stradomer<\/a>, creates engineered compounds for autoimmune disease therapies. <a href=\"http:\/\/www.niams.nih.gov\/Health_Info\/Autoimmune\/default.asp\">Autoimmune diseases<\/a> are those where the immune system attacks healthy cells in the body by mistake; examples are multiple sclerosis and myasthenia gravis, a neuromuscular disorder.<\/p>\n<p>One of Gliknik&#8217;s compounds in development is GL-2045, a protein designed to mimic the efficacy and safety of intravenous immunoglobulin in patients with autoimmune diseases. Intravenous immunoglobulin is used to treat a number of immune disorders, and is usually produced from human plasma. Gliknik expects to test GL-2045 as a treatment for myasthenia gravis, and later with other neurological conditions.<\/p>\n<p>The company plans to apply the new investment to further develop GL-2045, says Gliknik&#8217;s chief scientist Norbert Riedel, and determine if other engineered peptides can complement intravenous immunoglobulin therapies based on plasma. Gliknik also expects to use the funds to advance its clinical immune-system booster compounds currently in clinical trials with patients with advanced cancers, including multiple myeloma and head and neck cancers.<\/p>\n<p><a href=\"https:\/\/www.baxter.com\/about_baxter\/scientific_excellence\/baxter_ventures\/index.html\">Baxter Ventures<\/a> that leads the funding round invests in companies that complement its current medical products an bioscience business lines. Gliknik&#8217;s other current investors, identified on its <a href=\"http:\/\/www.gliknik.com\/about\/investors.php\">Web site<\/a>, are LifeTech Development Partners and Maryland Health Care Product Development Corporation.<\/p>\n<p>Read more:<\/p>\n<ul>\n<li><a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=11247\">FDA Approves Oral Drug for Relapsing Multiple Sclerosis<\/a><\/li>\n<li><a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=10769\">Pfizer, Biotech to Partner on Autoimmune Disorders<\/a><\/li>\n<li><a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=10325\">Janssen to Fund Research\/Modeling for Multiple Sclerosis<\/a><\/li>\n<li><a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=9862\">Trial Shows Long-Term Benefit of Multiple Sclerosis Drug<\/a><\/li>\n<li><a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=5364\">Baxter Sets Up Venture Fund for New Therapies<\/a><\/li>\n<\/ul>\n<p style=\"text-align: left;\">Photo:\u00a0<a href=\"http:\/\/www.flickr.com\/photos\/dborman2\/3290560161\/\">borman818\/Flickr<\/a><\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gliknik Inc., a biopharmaceutical company in Baltimore, raised $4.9 million in series B funds, the second series of financing after initial start-up. Baxter Ventures led the funding round, joined by the company&#8217;s existing investors. Gliknik is a developer of therapies for patients with cancer and immune disorders that use the power of the immune system [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[31,21,51,23,55,24,64,27,19],"class_list":["post-11549","post","type-post","status-publish","format-standard","hentry","category-finance","tag-biomedical","tag-biotech","tag-cancer","tag-equity","tag-genomics","tag-investment","tag-life-sciences","tag-pharmaceuticals","tag-venture-capital"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/11549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11549"}],"version-history":[{"count":4,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/11549\/revisions"}],"predecessor-version":[{"id":11553,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/11549\/revisions\/11553"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11549"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}